Roche's prasinezumab Phase IIb PADOVA study showed a trend towards slowing motor progression in early-stage Parkinson's disease, but missed statistical significance in the primary endpoint.A pre-specified analysis revealed a more pronounced effect in patients treated with levodopa.Positive trends were observed in multiple secondary and exploratory endpoints, suggesting potential clinical efficacy.Prasinezumab remains well-tolerated with no new safety concerns.Further data evaluation and collaboration with health authorities will determine next steps.Phase II PASADENA and PADOVA extension studies continue to explore observed effects.Prasinezumab targets alpha-synuclein aggregation, a key pathological feature in Parkinson's disease.Roche aims to develop disease-modifying treatments to slow progression and potentially prevent Parkinson's disease.Parkinson's disease affects over 10 million people globally and is a leading neurological disorder.Roche is investigating multiple approaches to address the underlying disease processes in Parkinson's disease.